AC Immune Shares Rise 19% as Firm Advances Alzheimer's Vaccine in Phase 1b/2a Trial
Source: Streetwise Reports  (7/16/20)
AC Immune SA shares set a new 52-week high after the Swiss biotech firm reported that interim data from its Phase 1b/2a phospho-Tau Alzheimer's Vaccine study reconfirms promising safety and Tau-specific immunogenicity observed in the prior clinical trial. More >

Taiwan Liposome Shares Rise 60% on Inhalable Liposomal HCQ Potential Covid-19 Treatment Claims
Source: Streetwise Reports  (7/15/20)
Shares of Taiwan Liposome Co. reached a new 52-week high after the company released a manuscript describing how its inhalable liposomal hydroxychloroquine may provide clinical benefit and offer a potential treatment for Covid-19. More >

Potential Covid-19 Treatment Is Ready for Prime Time
Source: Streetwise Reports  (7/14/20)
Small-cap Algernon Pharmaceuticals is about to begin a multinational Phase 2b/3 trial for Ifenprodil, a repurposed drug with a known safety record. More >

INmune Bio Shares Double after Reporting Positive Phase 1b Alzheimer's Trial Data
Source: Streetwise Reports  (7/14/20)
Shares of INmune Bio reached a new 52-week high after the company reported interim data from its Phase 1b study of XPro1595 that demonstrated decreased neuroinflammation in Alzheimer's patients. More >

BioNTech Shares Rise as FDA Grants It and Partner Pfizer Fast Track Status for Two Covid-19 Vaccine Candidates
Source: Streetwise Reports  (7/13/20)
Shares of BioNTech SE traded 15% higher after the company reported that, together with its partner Pfizer, it has received FDA Fast Track designation for two separate mRNA-based vaccine candidates against SARS-CoV-2. More >

Threat Detection Company Forms Partnership to Advance Covid-19 Pathogen Screening
Source: Streetwise Reports  (7/12/20)
Patriot One Technologies reported it is collaborating with ecoMine Technologies to advance pathogen screening applications as part of Canada's Digital Technology Supercluster's Covid-19 program. More >

Altimmune Shares Up 20% Upon Forming Partnership for Intranasal COVID-19 Vaccine
Source: Streetwise Reports  (7/9/20)
Altimmune shares reached a new 52-week high after the company reported it is collaborating with DynPort Vaccine on U.S. government funding efforts for AdCOVIDâ„¢, its COVID-19 vaccine candidate. More >

Biotech with Phase 3 Rheumatoid Arthritis and Psoriasis Trials Raises Capital, Now 'Funded Through Catalysts'
Source: Streetwise Reports  (7/8/20)
An update on Can-Fite BioPharma's multiple drug treatment trials is provided in a Dawson James report. More >

Preclinical COVID-19 Vaccine Data 'Encouraging'
Source: Streetwise Reports  (7/8/20)
Updates on Sorrento Therapeutics' two coronavirus-related products are provided in an H.C. Wainwright & Co. report. More >

Biopharma Starts Enrollment Screening for Phase 2 Pulmonary Fibrosis, Cough Trial
Source: Streetwise Reports  (7/8/20)
In the study, Algernon Pharmaceuticals will test an existing drug that is being repurposed for these indications. More >

Analyst: G1 Minimizes the Carnage of Chemotherapy
Source: Streetwise Reports  (7/1/20)
ROTH Capital Partners initiates coverage on U.S. oncology biopharma G1 Therapeutics that is now filing an NDA. More >

'Undervalued' Biopharma Gets Breakthrough Status for Alzheimer's Agitation Drug
Source: Streetwise Reports  (7/1/20)
Axsome Therapeutics' latest news and clinical outlook are discussed in an H.C. Wainwright & Co. report. More >

Life Sciences Firm Submits IND Application to FDA for Phase 3 COVID-19 Study
Source: Streetwise Reports  (7/1/20)
Revive Therapeutics submitted an Investigational New Drug Application to the FDA for a Phase 3 confirmatory study of Bucillamine for treatment in SARS-CoV-2. More >

Akero Therapeutics Shares Rise on Positive Data from Phase 2a NASH Study
Source: Streetwise Reports  (7/1/20)
Akero Therapeutics shares traded 28% higher and established a new 52-week high after the company reported that it recorded positive histological data across all Efruxifermin dosage groups in its Phase 2a BALANCED Study in NASH patients. More >

Biopharma's Multinational COVID-19 Study Receives US Ethics Approval
Source: Streetwise Reports  (6/30/20)
Algernon Pharmaceuticals is seeking approved participation from Australia, Romania and the Philippines as well. More >

Vaxart Shares Rise 95% After Signing Agreement for Oral Tablet COVID-19 Vaccine
Source: Streetwise Reports  (6/25/20)
Shares of Vaxart Inc. nearly doubled after the company reported that it has signed a Memorandum of Understanding with Attwill Medical Solutions Sterilflow to enable production of a billion or more tablet COVID-19 vaccine doses annually. More >

Biotech's New Mesothelioma Trial Data Show Efficacy, Immunogenicity
Source: Streetwise Reports  (6/24/20)
These results of a study evaluating Targovax's lead candidate are reviewed and commented on in an H.C. Wainwright & Co. report. More >

Translate Bio and Sanofi Expand Partnership to Develop mRNA Vaccines
Source: Streetwise Reports  (6/23/20)
Translate Bio shares traded 45% higher reaching a new 52-week high after the company reported that it is expanding its collaboration with Sanofi Pasteur to develop mRNA vaccines across all infectious disease areas. More >

FDA Grants Ampio Pharma Approval to Begin Phase 1 Trial in COVID-19 Patients
Source: Streetwise Reports  (6/19/20)
Ampio Pharmaceuticals' shares traded higher after the company reported that the FDA cleared the firm to proceed with human trials of its Investigative New Drug application for intravenous AmpionTM for treatment in COVID-19 affected patients on supplemental oxygen. More >

Alpine Immune Shares Soar 160% on Global Option and License Agreement with AbbVie
Source: Streetwise Reports  (6/18/20)
Shares of Alpine Immune Sciences set a new 52-week high after the company reported that it entered into an exclusive worldwide option and license agreement with AbbVie Inc. to develop and commercialize ALPN-101. More >

Regenerative Medicine Firm Reports Early Results from COVID-19 Trials
Source: Streetwise Reports  (6/17/20)
Pluristem Therapeutics' coronavirus clinical studies and financing are discussed in a Dawson James report. More >

Biopharma Launches Trial Testing Nitric Oxide as COVID-19 Treatment
Source: Streetwise Reports  (6/17/20)
The design, timeline and takeaways of Beyond Air's study are presented in a ROTH Capital Partners report. More >

Eli Lilly Trades Up 15% on Positive Phase 3 Breast Cancer Trial Results
Source: Streetwise Reports  (6/16/20)
Eli Lilly shares set a new 52-week high price after the company reported that its Verzenio® (abemaciclib) significantly reduced the risk of cancer returning in people with high risk HR+, HER2- early breast cancer. More >

Life Sciences Firm Expands Collaboration Efforts with Major U.S. University to Develop Psilocybin-Based Medicines
Source: Streetwise Reports  (6/15/20)
Revive Therapeutics Ltd. reported it has expanded its research partnership for novel formulation development and clinical research of psilocybin with the University of Wisconsin-Madison. More >

Edesa Shares Double Upon Gaining Approval to Initiate Phase 2/3 COVID-19 Study
Source: Streetwise Reports  (6/15/20)
Shares of Edesa Biotech traded more than 100% higher after the company reported that it had received regulatory approval from Health Canada to initiate a Phase 2/3 study of its investigational drug EB05 in COVID-19. More >